Takagi Hisato, Ando Tomo, Umemoto Takuya
Department of Cardiovascular Surgery, Shizuoka Medical Center, Shizuoka, Japan.
Department of Cardiology, Detroit Medical Center, Detroit, MI, United States.
Int J Cardiol. 2017 Jun 1;236:427-431. doi: 10.1016/j.ijcard.2017.01.075. Epub 2017 Jan 11.
To determine whether follow-up survival is better after elective endovascular aneurysm repair (EVAR) than open surgical repair (OSR) for intact abdominal aortic aneurysm (AAA), we combined 5-year survival curves themselves of EVAR and OSR in randomized controlled trials (RCTs) and propensity-score matched (PSM) studies.
Eligible studies were RCTs or PSM studies of elective EVAR versus OSR enrolling patients with intact AAA and reporting 5-year (at least) survival curves. Data regarding detailed inclusion criteria, duration of follow-up, and survival curves were abstracted from each individual study. In case of crossing of the combined survival curves, a pooled late-phase (between the crossing time and 5years) hazard ratio (HR) for all-cause mortality was calculated.
Our search identified 7 eligible studies (including 2 RCTs and 5 PSM studies) enrolling a total of 92,333 patients with AAA assigned to EVAR or OSR. Pooled survival rates after EVAR and OSR were 98.1% and 96.1 at 1month, 94.2% and 93.1% at 1year, 85.1% and 86.8% at 3years, and 75.8% and 78.8% at 5years, respectively. The survival curves crossed at 1.8years with the survival rate of 90.5%. A pooled late-phase (between 1.8years and 5years) HR for calculated from data of the combined survival curves significantly favored OSR (1.29, 95% confidence interval, 1.24 to 1.35; p<0.00001).
For intact AAA, although survival was better immediately after elective EVAR than OSR, the survival curves crossed at 1.8years. Thereafter until 5years, survival was worse after EVAR than OSR.
为了确定对于完整腹主动脉瘤(AAA)患者,选择性血管内动脉瘤修复术(EVAR)后的随访生存率是否优于开放手术修复术(OSR),我们将随机对照试验(RCT)和倾向评分匹配(PSM)研究中EVAR和OSR的5年生存曲线进行了合并。
符合条件的研究为关于选择性EVAR与OSR对比的RCT或PSM研究,纳入完整AAA患者并报告(至少)5年生存曲线。从每项独立研究中提取有关详细纳入标准、随访时间和生存曲线的数据。如果合并生存曲线交叉,则计算全因死亡率的合并晚期(交叉时间至5年之间)风险比(HR)。
我们的检索确定了7项符合条件的研究(包括2项RCT和5项PSM研究),共纳入92333例被分配接受EVAR或OSR的AAA患者。EVAR和OSR后1个月的合并生存率分别为98.1%和96.1%,1年时为94.2%和93.1%,3年时为85.1%和86.8%,5年时为75.8%和78.8%。生存曲线在1.8年时交叉,生存率为90.5%。根据合并生存曲线数据计算的合并晚期(1.8年至5年之间)HR显著有利于OSR(1.29,95%置信区间,1.24至1.35;p<0.00001)。
对于完整AAA患者,尽管选择性EVAR术后即刻生存率优于OSR,但生存曲线在1.8年时交叉。此后至5年,EVAR后的生存率低于OSR。